Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03680092 · ClinicalTrials.gov registry record · Phase 2
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
A Phase 2 study of Hematologic Neoplasms and GvHD, sponsored by Dimitrios Tzachanis, MD PhD.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT03680092 is a Phase 2 study of Hematologic Neoplasms and GvHD that has completed, run by Dimitrios Tzachanis, MD PhD. The registered enrollment target is 43 participants, below the 1,024-participant average among 20 other Hematologic Neoplasms trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03680092, a Phase 2 study of Hematologic Neoplasms and GvHD, has completed, sponsored by Dimitrios Tzachanis, MD PhD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate whether the combination of cyclophosphamide and abatacept versus the treatment used in standard of care will reduce the incidence of moderate and severe chronic graft-versus-host disease (GVHD) following hematopoietic stem cell transplantation. GVHD occurs when the cells from your donor (the graft) see your body's cells (the host) as different and attack them.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Tacrolimus
- DRUG Methotrexate
- DRUG abatacept
Study Locations (1)
California
- UC San Diego Moores Cancer Center - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2019-11-26 |
| Est. Completion | 2023-06-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03680092
The ClinicalTrials.gov registry entry for NCT03680092 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,024-participant average among 20 other Hematologic Neoplasms trials with a reported enrollment target (96% lower). The listed sponsor is Dimitrios Tzachanis, MD PhD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hematologic Neoplasms appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT03680092 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03680092 about?
NCT03680092 is a clinical study titled "Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation". The purpose of this study is to investigate whether the combination of cyclophosphamide and abatacept versus the treatment used in standard of care will reduce the incidence of moderate and severe chronic graft-versus-host disease (GVHD) following hematopoietic stem cell transplantation. GVHD occurs...
What is the current status of trial NCT03680092?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2019-11-26. Estimated completion is 2023-06-15.
What conditions does trial NCT03680092 study?
This clinical trial studies the following conditions: Hematologic Neoplasms, GvHD.
What interventions are being tested in trial NCT03680092?
The interventions under investigation include: Cyclophosphamide (DRUG), Tacrolimus (DRUG), Methotrexate (DRUG), abatacept (DRUG).
Who is sponsoring clinical trial NCT03680092?
This trial is sponsored by Dimitrios Tzachanis, MD PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03680092 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fludarabine and Total Body Irradiation 800 Centigray (cGy) or 1125 cGy For Allogeneic Stem Cell Transplant Using Graft Versus Host Disease Prophylaxis With Post-Transplant Cyclophosphamide and Tacrolimus, Without Mycophenolate Mofetil
ACTIVE NOT RECRUITING · Phase 2
-
Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant
COMPLETED · Phase 2
-
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
COMPLETED · Phase 2
-
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant
COMPLETED · Phase 2
-
Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies
COMPLETED · Phase 2
-
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.